Ahead of CapMan's Q3 2025 results on 6 November, we only make minor revisions to our adjusted EBIT e...
Following Suominen's profit warning on 15 October, we cut our estimates, which results in a slightly...
* Seasonally weaker volumes to weigh on earnings * 10-12% '26e-'27e sales growth, 21-22% EBIT margin...
Redeye comments on Faron’s updated BEXMAB data presented at the ESMO 2025 congress, which further st...
* Q3 softer due to sizeable customer trimming '25 volumes * '25e-'27e sales cut by 11-6% and '26e-'2...
YIT reports its Q3 results on October 30th. The quarter is expected to be quite slow, with housing u...
Redeye provides an initial take following Q-linea’s Q3 2025 report.
Redeye anticipates a pronounced decline in Xbrane’s share at market open.
Redeye updates its estimates and fair value range following Waystream’s Q3 report.
Redeye is positive about the acceptance of Paxman’s PLCS system for CIPN into the FDA’s Safer Techno...
* Q3 report due on 23 October * We cut 2025e EBITA by 3% but raise 2026e-2027e by 3-2% * Share is tr...
* Finland-based GRK Infra raises its 2025 guidance * Sees EUR 57m-64m earnings, up ~20% from previou...
Redeye provides a short comment on GB-A negative decision relating to reimbursement on the German ma...
Redeye notes an interesting press release from Genovis confirming a SEK11m order from a global pharm...
Stabila utdelningar eller fallande trend? Redeye tittar närmare på bolagets utdelningar.
Administer announced a second intended acquisition from Sarastia, this time targeting the financial ...
Q4 results were broadly in line with expectations, though regional performance diverged from our for...
DT reports Q3 results on Oct 30. Q3 will be another weak quarter, while Q4 could be relatively bette...
Redeye considers I-Tech’s Q3 figures relatively soft, missing our top-line estimate by 10% and EBITD...
Redeye comments on Xbrane following yesterday’s press release, which provided updates on a condition...
